Sarepta Therapeutics (NASDAQ:SRPT) Given “Neutral” Rating at Cantor Fitzgerald

Cantor Fitzgerald reiterated their neutral rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research note issued to investors on Monday morning, Marketbeat Ratings reports.

A number of other equities research analysts also recently commented on the stock. Piper Sandler downgraded shares of Sarepta Therapeutics from an “overweight” rating to a “neutral” rating and reduced their price objective for the company from $70.00 to $36.00 in a research report on Monday. BMO Capital Markets lowered shares of Sarepta Therapeutics from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $120.00 to $70.00 in a research report on Monday. Needham & Company LLC lowered their price target on shares of Sarepta Therapeutics from $125.00 to $50.00 and set a “buy” rating on the stock in a research note on Monday. Guggenheim reduced their price objective on shares of Sarepta Therapeutics from $112.00 to $98.00 and set a “buy” rating for the company in a research note on Wednesday, May 7th. Finally, Deutsche Bank Aktiengesellschaft decreased their price objective on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating on the stock in a report on Wednesday, March 19th. One analyst has rated the stock with a sell rating, twelve have given a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $70.76.

Sarepta Therapeutics Stock Down 3.7%

SRPT opened at $20.77 on Monday. The business has a 50 day moving average price of $44.31 and a two-hundred day moving average price of $84.36. The company has a quick ratio of 2.46, a current ratio of 4.02 and a debt-to-equity ratio of 1.00. The company has a market cap of $2.04 billion, a PE ratio of -7.72 and a beta of 0.61. Sarepta Therapeutics has a 52 week low of $18.30 and a 52 week high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing the consensus estimate of $2.20 by ($5.62). The company had revenue of $744.86 million for the quarter, compared to analysts’ expectations of $685.75 million. Sarepta Therapeutics had a negative return on equity of 14.88% and a negative net margin of 11.12%. Sarepta Therapeutics’s revenue for the quarter was up 80.2% compared to the same quarter last year. During the same quarter last year, the company earned $0.73 EPS. As a group, research analysts anticipate that Sarepta Therapeutics will post 2.67 EPS for the current year.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its position in Sarepta Therapeutics by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 9,085,456 shares of the biotechnology company’s stock worth $1,104,701,000 after purchasing an additional 117,904 shares during the last quarter. Capital International Investors boosted its holdings in shares of Sarepta Therapeutics by 38.9% in the 4th quarter. Capital International Investors now owns 8,697,137 shares of the biotechnology company’s stock valued at $1,057,482,000 after purchasing an additional 2,437,855 shares during the last quarter. Farallon Capital Management LLC grew its stake in shares of Sarepta Therapeutics by 11.1% during the 4th quarter. Farallon Capital Management LLC now owns 2,865,100 shares of the biotechnology company’s stock valued at $348,368,000 after buying an additional 285,100 shares during the period. Wellington Management Group LLP raised its position in shares of Sarepta Therapeutics by 27.9% in the 1st quarter. Wellington Management Group LLP now owns 2,646,619 shares of the biotechnology company’s stock worth $168,907,000 after buying an additional 577,848 shares during the period. Finally, T. Rowe Price Investment Management Inc. lifted its stake in shares of Sarepta Therapeutics by 2.1% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 1,997,991 shares of the biotechnology company’s stock valued at $127,512,000 after purchasing an additional 41,408 shares in the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.